TICKERNERD
Menu
BLCOBLCOHealthcare · Medical Instruments & Supplies

BLCO Stock Forecast: Bausch + Lomb Corp. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$18
+0.34% on the day

The 13 Wall Street analysts covering Bausch + Lomb Corp. hold a median 12-month price target of $18 — +2.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 8 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.4B
Ticker Nerd rank
87 / 100
Median analyst target
$18
Analysts covering
13
Revenue$1.4B+9.1% y/y
Operating income$108.0M
Net income−$10.0M
Free cash flow$82.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
+6.0%
YTD
+4.2%
1Y
+16.3%
From 52W high
−4.4%
From 52W low
+24.2%
$14
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BLCO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bausch + Lomb Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
88
Volatility
84
Growth
80
Momentum
69
Accruals
69
Revisions
58
Issuance
42
Size
20

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.

Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BLCO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLCO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$14$16$18$20$22$24Oct 25Jan 26Apr 26Jul 26BLCOHigh $23Median $18Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
5 Buy7 Hold1 Sell
Low $16Median $18High $23

The green dot is the last close — the median target sits +2.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026Leerink PartnersInitiatesOutperform$24
28 Aug 2026HC Wainwright & Co.ReiteratesBuy$21
3 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $21
30 July 2026UBSMaintainsBuy—
30 July 2026UBSMaintainsBuy$21 → $23
28 July 2026UBSInitiatesBuy$21
28 July 2026UBSInitiatesBuy—
6 July 2026Evercore ISI GroupMaintainsIn-Line$16 → $17
6 July 2026Evercore ISI GroupMaintainsIn-Line—
30 Apr 2026Evercore ISI GroupMaintainsIn-Line—
6 Apr 2026Evercore ISI GroupMaintainsIn-Line—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
19 Feb 2026BarclaysMaintainsEqual-Weight—
19 Feb 2026CitigroupMaintainsBuy—
19 Feb 2026StifelMaintainsHold—
19 Feb 2026Wells FargoMaintainsEqual-Weight—
17 Feb 2026StifelMaintainsHold—
5 Jan 2026Evercore ISI GroupDowngradeIn-Line—
2 Dec 2025Morgan StanleyUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLCO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BLCO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Bausch + Lomb Corp. returned +16.3% against +18.5% for the S&P 500, dividends included.

BLCO vs S&P 500, last 12 monthsTotal return, rebased to 100
95100105110115120Oct 25Jan 26Apr 26Jul 26BLCOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BLCO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.0%
Analysts raising
8
Analysts cutting
2
Fundamentals

Bausch + Lomb Corp. (BLCO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.4×

Cheaper than 95% of US stocks

Price / sales
1.2×

Cheaper than 65% of US stocks

Price / book
1.0×

Cheaper than 74% of US stocks

EV / EBITDA
13.7×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
9.1%

Higher than 49% of US stocks

Earnings growth (YoY)
9.1%

Higher than 47% of US stocks

Gross margin
62.2%

Higher than 75% of US stocks

Operating margin
7.7%

Higher than 60% of US stocks

Net margin
−3.2%

Higher than 26% of US stocks

Returns & dividend
Return on equity
−2.5%

Higher than 41% of US stocks

Return on assets
1.8%

Higher than 57% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bausch + Lomb Corp. (BLCO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bausch + Lomb Corp. has a market value of $6.4B and an enterprise value of $11.2B.

  • Revenue in the twelve months to 30 June 2026: $5.3B. The latest quarter grew 9.1% year on year.

  • Net income over the same four quarters: −$163.0M, a −3.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.48.

  • Free cash flow in the twelve months to 30 June 2026: $137.0M.

  • Shares outstanding: 357.1M.

  • Trailing P/E: −17.4×; forward P/E: 16.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bausch + Lomb Corp. employs 13,000 people — $410K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

BLCO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BLCOBausch + Lomb Corp.$6.4B
87
MMEDMiniMed Group, Inc.$6.5B
2
TFXTeleflex, Inc.$6.1B
81
STVNStevanato Group SpA$5.5B
64
MMSIMerit Medical Systems, Inc.$5.2B
92
ATRAptarGroup, Inc.$8.2B
49
NVSTEnvista Holdings Corp.$4.5B
99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bausch + Lomb Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BLCO news & analysis

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Business Wire · 2 Sept 2026positive

Bausch + Lomb announced the publication of new research on real world experience with its enVista Aspire and enVista Aspire toric intraocular lenses. The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered good distance and functional intermediate vision.

Why it matters — This published research supporting the performance of a Bausch + Lomb product line may help reinforce the company's position in the intraocular lens market.

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Business Wire · 1 Sept 2026neutral

Bausch + Lomb announced findings from a new survey revealing a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these life stages, with only 14% of peri- and menopausal women recognizing it.

Why it matters — The survey highlights a potential opportunity for Bausch + Lomb to educate consumers about dry eye as a perimenopause and menopause symptom, which could relate to its eye health product portfolio.

Bausch + Lomb Advances Two First-in-Class Eye Health Therapies

Zacks Investment Research · 25 Aug 2026positive

Bausch + Lomb is advancing two first-in-class eye-health therapy candidates following positive trial results. The two candidates have a combined estimated peak sales potential exceeding $2 billion, according to the report.

Why it matters — Progress on these two high-potential pipeline candidates indicates development momentum in Bausch + Lomb's eye-health portfolio, an area central to its business.

Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript

Seeking Alpha · 25 Aug 2026neutral

A transcript was published of Bausch + Lomb Corporation discussing its results and development plans for a dual action dry eye medicine and its lead ocular surface pain candidate.

Why it matters — The discussion provides BLCO watchers with management's perspective on the progress and pipeline plans for two key ophthalmic drug candidates.

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

MarketBeat · 25 Aug 2026neutral

Bausch + Lomb said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.

Why it matters — The advancement of this dry eye candidate to Phase III signals pipeline progress for BLCO, though the missed primary endpoint at day 29 may warrant scrutiny from watchers.

FAQ

Frequently asked questions about BLCO stock

What is the BLCO stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Bausch + Lomb Corp. have a median 12-month price target of $18, with estimates ranging from $16 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLCO stock a buy right now?

Of the 13 analysts covering Bausch + Lomb Corp., 5 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bausch + Lomb Corp. 87 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLCO?

As at 8 Sept 2026, Bausch + Lomb Corp. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will BLCO stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +2.6% from the last close, and Ticker Nerd's factor model ranks Bausch + Lomb Corp. 87 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLCO stock forecast for 2030?

No analyst covering Bausch + Lomb Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLCO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $23 over the next 12 months.

How has BLCO stock performed over the past year?

Bausch + Lomb Corp. returned +16.3% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bausch + Lomb Corp. do?

Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision care, surgical care, and ophthalmic pharmaceuticals. Bausch + Lomb offers contact lenses, lens care solutions, eye drops, vitamins and supplements, and prescription therapies for a range of eye conditions.

What is the latest news on BLCO?

The most recent item we track (Business Wire, 2 Sept 2026): "Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience". Bausch + Lomb announced the publication of new research on real world experience with its enVista Aspire and enVista Aspire toric intraocular lenses. The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered good distance and functional intermediate vision.

Company

About Bausch + Lomb Corp.

Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision care, surgical care, and ophthalmic pharmaceuticals. Bausch + Lomb offers contact lenses, lens care solutions, eye drops, vitamins and supplements, and prescription therapies for a range of eye conditions. Its surgical portfolio includes intraocular lenses, ophthalmic surgical devices, and instruments used in cataract and other eye procedures. The company serves consumers, eye care professionals, and healthcare providers across international markets, supporting routine vision maintenance as well as more specialized clinical treatment. Headquartered in Vaughan, Ontario, Canada, Bausch + Lomb focuses exclusively on eye health and remains a recognized name in the medical devices and ophthalmic goods industry.

CEO Mr. Brenton L. Saunders J.D. · 13,000 employees · Canada · https://www.bausch.com